Τίτλος:
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in
Malignant Pleural Mesothelioma A Single Institution Study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective: The combinations of cisplatin-pemetrexed and
cisplatin-gemcitabine are considered the standard systemic therapy for
malignant pleural mesothelioma (MPM), which is a rapidly progressive
tumor. The purpose of the present study is to evaluate the efficacy,
safety, and clinical benefit of the gemcitabine plus docetaxel regimen
in the second-line treatment of this disease.
Patients and Methods: A total of 37 patients with MPM were treated with
the combination of docetaxel (80 mg/m(2)) and gemcitabine (1000 mg/m(2))
on day 1 and 14 of a 28-day cycle. The regimen was repeated for a
maximum of 6 cycles or until disease progression or unacceptable
toxicity.
Results: There was partial response of the disease in 7 patients
(18.9%), whereas it remained stable in 23 patients (62.2%) and
progressed in 7 patients (18.9%). The median time to disease
progression was 7 months (range: 5.8-8.2 months) with a mean survival of
16.2 months (range: 13-19.3 months).
Conclusion: The biweekly administration of docetaxel and gemcitabine,
along with granulocyte colony-stimulating factor support, constitutes a
safe, tolerable, and convenient regimen for the treatment of MPM,
suggesting that this combination may be a viable option, especially in
previously treated patients.
Συγγραφείς:
Tourkantonis, Ioannis
Makrilia, Nektaria
Ralli, Maria and
Alamara, Christina
Nikolaidis, Ilias
Tsimpoukis, Sotirios and
Charpidou, Andriani
Kotanidou, Anastasia
Syrigos, Kostas
Περιοδικό:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY - CANCER CLINICAL TRIALS
Εκδότης:
Lippincott, Williams & Wilkins
Λέξεις-κλειδιά:
docetaxel; gemcitabine; mesothelioma; second-line chemotherapy
DOI:
10.1097/COC.0b013e3181cae90e
